/INMB
INMB Stock - INmune Bio, Inc.
Healthcare|BiotechnologyNASDAQ
$1.83+0.55%
+$0.01 (+0.55%) • Dec 19
69
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.28
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.83
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+1102.2%upside
Target: $22.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for INMB
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$1.81 – $1.85
TARGET (TP)$22.00
STOP LOSS$1.68
RISK/REWARD1:134.5
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.92
52W High$11.64
52W Low$1.38
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $14,000 | $155,000 | $374,000 | $181,000 | $11,000 |
| Gross Profit | $14,000 | $155,000 | $374,000 | $181,000 | $11,000 |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating Income | $-42,635,000 | $-29,741,000 | $-25,951,000 | $-29,153,000 | $-12,228,000 |
| Net Income | $-42,082,000 | $-30,008,000 | $-27,299,000 | $-30,340,000 | $-12,099,000 |
| Net Margin | -300585.7% | -19360.0% | -7299.2% | -16762.4% | -109990.9% |
| EPS | $-2.11 | $-1.67 | $-1.52 | $-1.88 | $-1.01 |
Company Overview
INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease. The company develops and commercializes product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma and patients with high-risk myelodysplastic syndrome; INB03, an immunotherapy that treats patients with hematologic malignancies and solid tumors; and XPro1595 for the treatment of Alzheimer's disease. The company has license agreements with Xencor, Inc.; Immune Ventures, LLC; University of Pittsburg; and University College London. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
5
63%
Hold / Neutral
2
25%
Sell / Underperform
1
13%
Analyst Consensus🟡 Mixed
5 Bullish3 Neutral/Bearish
Price Targets
$15
Average Target
↑ 732.2% Upside
Now
$1
Low
$15
Average
$23
High
Based on 7 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| July 1st 2025 | BTIG Research | Downgrade | Neutral | - |
| July 1st 2025 | Scotiabank | Downgrade | Sector Underperform | $0.6 |
| January 28th 2025 | Rodman & Renshaw | Initiation | Buy | $23 |
| October 21st 2024 | Alliance Global Partners | Initiation | Buy | $20 |
| September 27th 2024 | Raymond James | Initiation | Outperform | $18 |
| August 22nd 2024 | Scotiabank | Initiation | Sector Outperform | $22 |
| June 1st 2023 | Robert W. Baird | Initiation | Outperform | $16 |
| May 24th 2022 | B. Riley Securities | Downgrade | Neutral | $7← $14 |
Earnings History & Surprises
INMBBeat Rate
53%
Last 19 quarters
Avg Surprise
-86.0%
EPS vs Estimate
Beats / Misses
10/8
1 met exactly
Latest EPS
$-0.24
Q4 2025
EPS Surprise History
Q1 24
-6.8%
$-0.47vs$-0.44
Q2 24
-15.1%
$-0.61vs$-0.53
Q3 24
+20.6%
$-0.50vs$-0.63
Q4 24
-22.4%
$-0.60vs$-0.49
Q1 25
+25.9%
$-0.40vs$-0.54
Q2 25
0.0%
$-0.43vs$-0.43
Q3 25
+8.1%
$-0.34vs$-0.37
Q4 25
+22.6%
$-0.24vs$-0.31
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 26, 2026 | $-0.28 | — | — | — |
Q4 2025 | Oct 30, 2025 | $-0.31 | $-0.24 | +22.6% | ✓ BEAT |
Q3 2025 | Aug 7, 2025 | $-0.37 | $-0.34 | +8.1% | ✓ BEAT |
Q2 2025 | May 8, 2025 | $-0.43 | $-0.43 | 0.0% | = MET |
Q1 2025 | Mar 27, 2025 | $-0.54 | $-0.40 | +25.9% | ✓ BEAT |
Q4 2024 | Oct 31, 2024 | $-0.49 | $-0.60 | -22.4% | ✗ MISS |
Q3 2024 | Aug 1, 2024 | $-0.63 | $-0.50 | +20.6% | ✓ BEAT |
Q2 2024 | May 9, 2024 | $-0.53 | $-0.61 | -15.1% | ✗ MISS |
Q1 2024 | Mar 28, 2024 | $-0.44 | $-0.47 | -6.8% | ✗ MISS |
Q4 2023 | Nov 1, 2023 | $-0.39 | $-0.48 | -23.1% | ✗ MISS |
Q3 2023 | Aug 7, 2023 | $-0.40 | $-0.36 | +10.0% | ✓ BEAT |
Q2 2023 | May 3, 2023 | $-0.02 | $-0.36 | -1700.0% | ✗ MISS |
Q1 2023 | Mar 2, 2023 | $-0.48 | $-0.32 | +33.3% | ✓ BEAT |
Q4 2022 | Nov 2, 2022 | $-0.59 | $-0.43 | +27.1% | ✓ BEAT |
Q3 2022 | Aug 3, 2022 | $-0.50 | $-0.38 | +24.0% | ✓ BEAT |
Q2 2022 | May 5, 2022 | $-0.60 | $-0.39 | +35.0% | ✓ BEAT |
Q1 2022 | Mar 3, 2022 | $-0.56 | $-0.55 | +1.8% | ✓ BEAT |
Q4 2021 | Nov 3, 2021 | $-0.43 | $-0.55 | -27.9% | ✗ MISS |
Q3 2021 | Aug 4, 2021 | $-0.33 | $-0.44 | -33.3% | ✗ MISS |
Q2 2021 | May 5, 2021 | $-0.28 | $-0.32 | -14.3% | ✗ MISS |
Latest News
INmune Bio Files For Common Stock Offering Of $65M Shares Of Common Stock
📉 NegativeBenzinga•Dec 19, 2025, 09:05 PM
INmune Bio Terminates $75M At-the-Market Sales Agreement With RBC Capital Markets And BTIG, Effective December 19, 2025; Prior To Termination, The Co Issued And Sold 1,353,469 Shares Of Common Stock Under The Sales Agreement, Raising Net Proceeds Of ~$10.5M
📉 NegativeBenzinga•Dec 10, 2025, 09:53 PM
INmune Bio Announces Published Overview Of Future Applications And Research Areas For Mesenchymal Stromal Cell Therapies, Such As INmune's CORDStrom Platform
📈 PositiveBenzinga•Dec 5, 2025, 12:11 PM
INmune Bio Announces New Neuroimaging Data From Phase 2 MINDFuL Trial Of XPro1595 In Patients With Early Alzheimer's Disease And Elevated Neuroinflammation
➖ NeutralBenzinga•Dec 1, 2025, 01:07 PM
INmune Bio Q3 Adj. EPS $(0.24) Beats $(0.33) Estimate
📈 PositiveBenzinga•Oct 30, 2025, 08:14 PM
INmune Bio Submits Manuscript Detailing Results Of Phase 2 MINDFuL Trial To Nature Portfolio Journal, npj Dementia
📈 PositiveBenzinga•Sep 29, 2025, 12:02 PM
INmune Bio Completes First Full-Scale Pilot Commercial Manufacturing Run Of CORDStrom, Umbilical Cord Tissue-Derived Mesenchymal Stromal Cell Therapy, For Treatment Of RDEB
📈 PositiveBenzinga•Sep 15, 2025, 12:10 PM
INmune Bio gains as trial for prostate cancer therapy succeeds
📈 PositiveSeeking Alpha•Aug 4, 2025, 01:00 PM
INmune Bio fails to meet main goal in Alzheimer's treatment study
📉 NegativeSeeking Alpha•Jun 30, 2025, 01:16 PM
INmune Bio reverses early gains after stock offering
📉 NegativeSeeking Alpha•Jun 27, 2025, 05:39 PM
INmune Bio surges ahead of mid-stage trial readout for Alzheimer's drug
📈 PositiveSeeking Alpha•Jun 27, 2025, 12:39 PM
Frequently Asked Questions about INMB
What is INMB's current stock price?
INmune Bio, Inc. (INMB) is currently trading at $1.83 per share. The stock has moved +0.55% today.
What is the analyst price target for INMB?
The average analyst price target for INMB is $22.00, based on 1 analyst.
What sector is INmune Bio, Inc. in?
INmune Bio, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is INMB's market cap?
INmune Bio, Inc. has a market capitalization of $0.05 billion, making it a small-cap company.
Does INMB pay dividends?
No, INmune Bio, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorALGS
Aligos Therapeutics, Inc.
$10.68
Mkt Cap: $0.1B
BRNS
Barinthus Biotherapeutics plc
$0.74
Mkt Cap: $0.0B
CVM
CEL-SCI Corporation
$4.91
Mkt Cap: $0.0B
FGEN
FibroGen, Inc.
$8.60
Mkt Cap: $0.0B
MRSN
Mersana Therapeutics, Inc.
$28.94
Mkt Cap: $0.1B
OKUR
OnKure Therapeutics, Inc.
$3.01
Mkt Cap: $0.0B
PDSB
PDS Biotechnology Corporation
$0.89
Mkt Cap: $0.0B
SKYE
Skye Bioscience, Inc.
$0.93
Mkt Cap: $0.0B
TPST
Tempest Therapeutics, Inc.
$3.12
Mkt Cap: $0.0B
XFOR
X4 Pharmaceuticals, Inc.
$3.60
Mkt Cap: $0.0B
Explore stocks similar to INMB for comparison